| Ytd | -4.07% | |
| 1y | -41.77% |
| Open | 2.79 | Prev Close | 2.78 | Low | 2.70 | High | 2.89 | Mkt Cap | 22.62M |
| Vol | 92.15K | Avg Vol | 1.05M | EPS | -5.38 | P/E | N/A | Forward P/E | -0.10 |
| Beta | 1.01 | Short Ratio | 8.34 | Inst. Own | 34.55% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.80 | 200-d Avg | 3.37 | 1yr Est | 5.67 |
CLRB News
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysi
https://www.sec.gov/Archives/edgar/data/1279704/000110465926063918/tm2614975d1_s1.htm
Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.33) per share which beat the an
Cellectar shares slip premarket after rally as CLOVER WaM data, financing plans, and technical signa
US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2
US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 e
Cellectar releases Phase 2b CLOVER WaM data showing strong response rates and durability, alongside
PINS: 19% | Pinterest shares are trading higher after the company reported better-than-expected Q1 f
83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response o
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused o
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused
Maxim Group analyst Jason McCarthy upgrades Cellectar Biosciences (NASDAQ:CLRB) from Hold to Buy
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.53) per share which beat the an
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Techn
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly los
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declini
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 104% to $1.3263 after the company anno
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednes
During Tuesday's trading, 505 companies set new 52-week lows.
Gainers MorphoSys (NASDAQ:MOR) stock moved upwards by 15.07% to $16.26 during Thursday's after